Federal prosecutors in the Middle District of Florida announced a civil settlement with an Orlando pharmacy and its pharmacist over alleged violations of the Controlled Substances Act. According to the settlement agreement, between December 22, 2021, and March 21, 2024, the pharmacy and pharmacist allegedly distributed Schedule V drugs improperly and committed multiple recordkeeping violations.
The case grew out of a Drug Enforcement Administration investigation. On March 21, 2024, DEA conducted an on-site inspection of the pharmacy and, as described in the settlement agreement, found dozens of recordkeeping violations of the Controlled Substances Act. The agency's diversion investigators handled the matter alongside the U.S. Attorney's Office.
The pharmacy surrendered its DEA registration for cause on May 2, 2024, and stopped operating in September 2025. Under the civil settlement, the pharmacy and pharmacist agreed to pay the United States $50,000 to resolve the allegations. A settlement of this kind resolves the government's claims and is not a determination of liability.
In announcing the resolution, the U.S. Attorney emphasized that pharmacies and pharmacists have an obligation to track and properly report the dispensing of controlled substances, and the DEA's Tampa Field Division said its diversion investigators would continue to pursue those who abuse the system.